Getein Biotech: Trade-Offs in Strategic Decision-Making under the Covid-19 Pandemic

內容大綱
As of the end of 2019, the point-of-care testing (POCT) products of Getein Biotech Inc., an important in vitro diagnostics (IVD) enterprise, had been successfully applied to the detection of many diseases, including cardiovascular diseases, inflammation, kidney diseases, and blood coagulation disorders. Its market share and output value were both among the highest in the industry. In addition to improving its core POCT products, Getein Biotech firmly grasped industry opportunities to accelerate expansion in key IVD segments and build a complete product system. However, with the impact of COVID-19 in 2020, the enterprise, unlike its competitors in this industry, failed to seize the opportunity of developing COVID-19 test kits. As a result, its profits fell sharply, and its competitive position in the industry faced huge challenges. At the beginning of 2021, due to uncertainties about the COVID-19 pandemic, the enterprise was forced to integrate its original resources and capabilities and adjust its development strategy in order to establish sustainable competitive advantages.
學習目標
This case is suitable for undergraduate and graduate level courses on strategy, especially those focused on strategic environment, competitive strategy, strategic choice, and organization resource optimization. After working through the case and assignment questions, students will be able to do the following:<ul><li>Accurately identify the opportunities and challenges brought by the external environment to industry development.</li><li>Outline the competitive advantages of Getein Biotech.</li><li>Identify the core competencies of Getein Biotech.</li><li>Determine the enterprise’s strategic positioning and choices in response to the changes in its external environment.</li></ul>
涵蓋主題
新增
新增